Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Trial details
- Registry ID
- NCT01953926
- Phase
- Phase 2
The FDA approved Neratinib (Nerlynx) on 17 Jul 2017.
Drug identity checked against registry records
Also recorded as Nerlynx
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsNCT01953926 | PBYI | Phase 2 | Terminated | 2023-01-02Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2017-07-17Day | Neratinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA208051", "applicant_as_listed_by_fda": "PUMA BIOTECH", "brand_names": ["NERLYNX"], "active_ingredients": ["NERATINIB MALEATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20170717", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |